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■
The prevalence of IBS in Europe and North America is estimated to range between 10% and 15%.
2,3
■ IBS-C has been shown to have a significant impact on the patient's life including reduced health-related quality of life (HRQoL), lost work productivity, and increased utilization of medical care and services when compared to general populations. 4 
■
Little is known about how HRQoL and the economic burden of IBS-C compare to other chronic conditions.
OBJECTIVE
■
The objective of this study was to evaluate the burden of IBS-C compared with nonfunctional gastrointestinal disorders (non-FGID), and with asthma, migraine, and rheumatoid arthritis (RA), on HRQoL, work productivity, and healthcare utilization.
METHODS
Data Source and Samples
■
The study population was comprised of respondents of the 2011 National Health and Wellness Survey (NHWS), a cross-sectional, self-administered Internet survey completed by a sample of adults (≥18 years).
The database contains disease-specific measures covering topics such as current health status, attitudes towards healthcare, lifestyle behaviors and HRQoL.
The NHWS began with annual surveys in the United States (US) in 1998 and expanded to Europe in 2000, followed by Japan and China in 2009, and most recently to Brazil and Russia in 2011.
In this study, data from the US, the United Kingdom (UK), and France were used, as sample size for IBS-C was sufficient for comparisons in these countries.
IBS-C Group
■
The NHWS contains a disease checklist that asks respondents: "Which of the following conditions have you experienced in the past twelve months?" Respondents select all conditions that apply from a list of approximately 30 additional conditions.
The IBS-C group consisted of those respondents reporting that they experienced both IBS and chronic constipation in the past 12 months.
Non-FGID Group
■
For purposes of evaluating the burden associated with IBS-C, comparisons were made with a sub-sample of NHWS respondents who reported no chronic or acute conditions on the conditions checklist (the "well" sample).
Chronic Condition Comparator Groups
■
The burden of IBS-C was also evaluated by comparing HRQoL, work productivity, and healthcare utilization between IBS-C and respondents who self-reported having asthma, RA, or migraine in the past 12 months on the conditions checklist.
Outcome Measures
HRQoL Burden ■ HRQoL was measured using the SF-12v2 Health Survey.
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■
The SF-12v2 is a generic health questionnaire consisting of 12 questions that are scored to produce eight scales: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. Work Impairment ■ Work impairment was measured using the Work Productivity and Activity Impairment (WPAI) questionnaire. 6 The WPAI is a 6-item, self-administered survey designed to measure the impact of a person's health on their work productivity (including amount of work time missed due to health problems, as well as decreases in productivity when working due to health problems) and non-work related activities (e.g., shopping, child care). Items on the WPAI are scored to produce the following measures:
-Percent work missed due to health issues (absenteeism) -Percent impairment while working due to health issues (presenteeism)
-Percent overall work impairment due to health issues -Percent daily activity impairment due to health issues
Utilization of Care and Services
■
Several questionnaire items fielded in the NHWS provide information on utilization of care and services for health problems. These items include: "How many times have you been to the emergency room for your own medical condition in the past six months?" and "How many times have you been hospitalized for your own medical condition in the past six months?"
Statistical Analyses
Prevalence of FGID
■
The number and frequency of respondents with IBS-C were compared across the general populations of the US, the UK, and France.
HRQoL Burden of IBS-C
The HRQoL burden associated with IBS-C in the NHWS was assessed by comparing SF-12v2 PCS and MCS scores of respondents with IBS-C to scores of respondents in the general non-FGID population sample of each country and to samples in each country with asthma, RA, and migraine. IBS-C, irritable bowel syndrome with constipation; SD, standard deviation.
To control for differences in sample characteristics, the mean PCS and MCS scores of the comparator samples (non-FGID, asthma, RA, and migraine) were adjusted to reflect the age and gender of the IBS-C sample using separate least squares multiple regression models with the SF-12v2 PCS and MCS as dependent variables.
Analysis of variance (ANOVA) models were used to test for significance of differences in PCS and MCS scores observed between the IBS-C and each comparison group.
Comparison of Work-Related Outcomes ■ Impairment in work-related outcomes (as measured by the WPAI domains) was compared between IBC-C and the non-FGID population and to the asthma, RA, and migraine samples within each country.
Samples were limited to those reporting that they currently work a paying job.
Pairwise Student t-tests were conducted to assess the statistical significance of differences in mean scores between comparison groups.
Healthcare Utilization -Number of ER Visits and Number of Hospitalizations
The frequency of healthcare utilization was compared between IBS-C and non-FGID groups and between IBS-C and asthma, RA, and migraine in each country.
The mean number of ER visits and the mean number of hospitalizations in the past six months was compared between groups. Pairwise t-tests were conducted to test the significance of differences in means between IBS-C and each comparator group.
RESULTS
Prevalence of IBS-C
■
The prevalence of IBS-C ranged from 0.67% to 1.03% across general population samples from the US, the UK, and France (Table 1) .
The majority of respondents reporting IBS-C were female in each country (>65%).
The average age of IBS-C respondents was very similar across countries, ranging from 47.8 to 49.8 years.
HRQoL Burden
■
The mean SF-12v2 PCS score for IBS-C respondents was significantly (P<0.001) lower (worse) than non-FGID respondents in all three countries (Figure 1 ). Differences in mean PCS scores were in the large effect size range.
In the US and UK mean SF-12v2 PCS scores for IBS-C respondents were significantly (P<0.05) lower than each of the three chronic condition groups (asthma, migraine, and RA); mean differences were in the moderate effect size range (Figure 1 ).
In France , the mean SF-12v2 PCS score for IBS-C was equal to or lower than each of the three chronic condition groups (Figure 1 ).
Figure 1. Comparison of SF-12 Physical Component Summary Scores Between IBS-C and non-FGID and Three Chronic Conditions in the US, the UK, and France
IBS-C, irritable bowel syndrome with constipation; non-FGID, nonfunctional gastrointestinal disorders; RA, rheumatoid arthritis.
■
In all three countries, mean SF-12v2 MCS scores for IBS-C respondents were significantly (P<0.001) lower (worse) than non-FGID respondents and each of the three chronic condition groups (asthma, migraine, and RA) (Figure 2 ).
The differences in mean MCS scores between IBS-C and each comparator group were all in the moderate to large effect size range. The mental health burden of IBS-C was clinically meaningful as the mean MCS score of IBS-C respondents was below the cut point score (<42) for a positive depression screen. 
CONCLUSIONS
■
In three countries, respondents with IBS-C showed significant deficits in HRQoL and work productivity, as well as elevated healthcare utilization compared with those without FGIDs and other chronic conditions.
Ironwood Pharmaceuticals, Inc. and Almirall S.A. were involved in the study design; collection, analysis, and interpretation of data; and decision to submit these data for presentation. In all three countries, IBS-C respondents reported significantly higher absenteeism (missed work time), presenteeism (impairment at work), overall work productivity loss (absenteeism and presenteeism), and impairment in performing daily activities compared with non-FGID respondents (all P<0.001) (Figure 3 ).
Compared to the three chronic conditions, IBS-C respondents reported significantly higher absenteeism (missed work time), presenteeism (impairment at work), overall work productivity loss (absenteeism and presenteeism), and impairment in performing daily activities in the US and France (all P<0.05) (Figure 3) .
In the UK, IBS-C respondents reported significantly higher presenteeism (impairment at work), overall work productivity loss (absenteeism and presenteeism), and impairment in performing daily activities compared to the three chronic conditions (all P<0.05). No significant differences in absenteeism were found between IBS-C and the three chronic conditions in the UK (Figure 3) . 
In both the UK and France, IBS-C respondents had a significantly (P<0.05) higher mean number of visits to the ER and hospital in the past 6 months compared with non-FGID respondents and respondents with migraine. IBS-C respondents also had a higher mean number of visits to the ER and hospital compared to respondents with asthma and RA; however, the differences did not reach statistical significance (Figure 4 ). 
